Last updated on April 20, 2014 at 17:20 EDT

NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica

March 11, 2013

LUND, Sweden, March 11, 2013 /PRNewswire/ –

NeuroVive, a leading mitochondrial medicine company, announces it has completed the
acquisition of a portfolio of novel cyclophilin inhibitors, technology platform assets and
related intellectual property rights from the UK biotech company Biotica Ltd. The
acquisition of these assets is important strategically as it will allow NeuroVive to
broaden and deepen its pipeline of novel mitochondrial medicines. No financial details of
the acquisition are being disclosed.

The portfolio of novel cyclophilin inhibitors is from a new class of molecules called
Sangamides based on a novel and unique chemistry platform of polyketides around which
NeuroVive has also acquired the intellectual property rights. These novel cyclophilin
inhibitors are expected to form the basis of the next-generation of NeuroVive products for
a broad range of diseases including cardio- and neuroprotection.

NeuroVive is presently developing a portfolio of products to treat important acute
cardiovascular and neurological conditions through mitochondrial protection. Its leading
products, CicloMulsion(R) and NeuroSTAT(R), are special formulations of the cyclophilin
inhibitor cyclosporine for two prioritized indications, the prevention of reperfusion
injury following stenting after myocardial infarction and traumatic brain injury
respectively. CicloMulsion(R) is currently in a 1,000 patient Phase III trial assessing
its ability to reduce overall mortality and the number of patients developing heart
failure following stenting in patients with myocardial infarction. This trial is expected
to complete recruitment by the end of 2013.

Mikael Bronnegard, CEO of NeuroVive Pharmaceutical said: “The acquisition of Biotica’s
pipeline of novel cyclophilin inhibitors will help to maintain NeuroVive’s current
position as one of the leading mitochondrial medicine companies and developers of
cyclophilin inhibitors for cardio- and neuroprotection. These molecules are the most
potent compounds for reducing mitochondrial dysfunction we have so far tested and with
their novel polyketide chemistry greatly strengthen our product pipeline. Ownership of
these Sangamides places NeuroVive in an excellent position to bring to market
significantly improved and patent protected follow-on products that will further enhance
the role of mitochondrial medicine across a range of diseases.”

About NeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical AB (http://www.neurovive.com) a leading mitochondrial
medicine company is developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection.

NeuroVive’s products are based on the cyclophilin inhibitor cyclosporine and work by
preventing the death of mitochondria in distressed cells and the subsequent cascade of
intracellular biochemical events that lead to secondary tissue damage following an acute
cardiac or traumatic brain injury.

NeuroVive’s lead product is CicloMulsion(R), the first cyclophilin inhibitor for the
treatment of reperfusion injuries following stenting. CicloMulsion(R) is currently in a
1000 patient Phase III European clinical trial evaluating its ability to reduce
reperfusion injuries in patients with myocardial infarction.

NeuroVive is also developing NeuroSTAT(R), a cyclophilin inhibitor, which is soon
expected to enter a Phase IIa clinical trial in patients with severe traumatic brain
injury. Both indications have huge medical need and for which there are currently no
approved pharmaceutical treatment options. Both CicloMulsion(R) and NeuroSTAT(R) are
special formulations of cyclosporine for use in acute cardiac and brain injury

NeuroVive’s pipeline includes novel cyclophilin inhibitors and as well drug candidates
that act on mitochondria to address energy regulation disorders.

NeuroVive’s shares are listed on the Swedish trading platform AktieTorget
(http://www.aktietorget.se). The AktieTorget market is focused on emerging,
entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic
stock exchange in Stockholm, Sweden.

About Biotica Technology Limited

Biotica Technology Limited is a privately-held biotechnology company that discovers
and develops novel polyketide-based therapeutics to create new medicines for a variety of
serious diseases. Its pipeline of therapeutic programs includes a new class of cyclophilin
inhibitors, called Sangamides, based on novel polyketide chemistry. Sangamides are amide
analogs of the naturally-occurring polyketide Sanglifehrin A, produced using Biotica’s
proprietary polyketide engineering technology.

Biotica was founded in 1996 and is based in Cambridge, UK. In January 2013 Biotica was
placed into administration.

Media and investor relations contacts

NeuroVive Pharmaceutical: Mikael Bronnegard
Email: info@neurovive.com
Phone No: +46-(0)70-299-62-64

Citigate Dewe Rogerson: Nina Enegren / David Dible
Email: nina.enegren@citigatedr.co.uk
Phone No: +44-207-282-1050

SOURCE NeuroVive Pharmaceutical AB

Source: PR Newswire